Compare Nu Holdings Ltd (NU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs TG Therapeutics Inc — how do they compare? Nu Holdings Ltd trades at $16.04 (market cap $74.30B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Nu Holdings Ltd is far larger — about 9.1× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and TG Therapeutics Inc for 16 Days on average.
| NU | TGTX | |
|---|---|---|
Market Cap | $74.30B | $8.16B |
Volume | 80,294,805 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $18.76 | $59.06 |
52-Week Low | $11.60 | $26.94 |
Typical Hold Time | 53 Days | 16 Days |
Enterprise Value | $96.91B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings (NU) trades at $15.92, up 2.18% with bullish technical signals from moving averages. The company demonstrates strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income reaching $2.9B. Recent news highlights acquisition speculation around Monzo and Goldman Sachs' bullish stance, though the stock remains volatile amid mixed earnings performance with two misses and one beat in recent quarters.
The outlook remains positive with 56.5% analyst buy ratings and a $16.53 consensus target, though risks include credit concentration (85% customer concentration in Brazil) and rising delinquencies. The stock trades near resistance at $16 with RSI at 91 suggesting overbought conditions, requiring careful entry timing despite strong growth fundamentals.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
